Invasive candidiasis and candidemia
Scynexis Inc. focuses its clinical research on serious fungal infections, with particular attention to invasive candidiasis and candidemia. The company’s trial activity centers on treatment strategies for bloodstream and deep-seated Candida infections in adult patients.
- Systemic antifungal therapy
- Candida bloodstream infection
- Invasive fungal disease
Research in this area reflects interest in managing complex infections that require sequential intravenous and oral antifungal treatment approaches.
Echinocandin-based treatment pathways
The sponsor’s research includes echinocandin-based regimens as a core element of therapy for candidemia and invasive candidiasis. This area highlights the role of initial IV antifungal treatment in serious yeast infections.
- Intravenous antifungal therapy
- Step-down treatment
- Severe Candida infection management
Clinical interest extends to treatment sequences that transition from parenteral to oral antifungal therapy in patients with systemic infection.
Ibrexafungerp and oral antifungal therapy
Scynexis Inc. also investigates ibrexafungerp as an oral antifungal option within treatment regimens for invasive candidiasis and candidemia. This therapeutic area is linked to maintaining antifungal coverage after initial IV treatment.
- Oral step-down therapy
- Antifungal sequencing
- Systemic Candida treatment
The research landscape includes comparison with established oral antifungal options used after echinocandin therapy.
Comparative antifungal treatment
The company’s clinical interest includes comparative evaluation of antifungal regimens for bloodstream Candida infections. Its research activity is directed toward treatment options used after initial control of infection with intravenous echinocandin therapy.
- Therapeutic comparison
- Antifungal regimen selection
- Management of invasive yeast disease
This area is relevant to patients requiring continued antifungal treatment for serious Candida-related illness.
